Pressmeddelande -
Sweden's ambassador Annika Thunborg attended the VASE conference in Mexico City
VASE 2018 (2nd International Vaccines Against Shigella and ETEC) in Mexico City gathered scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe to share research and ideas toward making Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines a reality. On-site was also Sweden's ambassador in Mexico, Annika Thunborg.
During the meeting the Ambassador presented Sweden's strategy in Global Health, the essential and lifesaving role new vaccines play in the field of diarrhoeal disease and how vaccines can reduce the imminent global threat of antibiotic resistance. Ambassador Thunborg further stated that Sweden, thanks to researchers at the University of Gothenburg and Scandinavian Biopharma, has the lead in developing the first vaccine against diarrhoeal disease caused by ETEC in the world.
Sweden's ambassador in Mexico Annika Thunborg and Dr. Richard Walker, Director of the Enteric Vaccine Initiative at PATH and in charge of the VASE Conference 2018, after her closing remarks during VASE 2018.
The Swedish ambassador did during the meeting meet key people from our partners, PATH, WHO, the Bill & Melinda Gates Foundation and global opinion leaders in the area.
Professor Ann-Mari Svennerholm, from the University of Gothenburg and Björn Sjöstrand, CEO of Scandinavian Biopharma, updates Ambassador Annika Thunborg about the very promising results from our Phase I/II study in Dhaka, Bangladesh.
Ambassador Annika Thunborg, Lorena Matus from Business Sweden, Björn Sjöstrand, Dr. Thomas Wierzba, Senior Scientist at PATH and Dr. Lou Bourgeois, Acting Director Enteric Vaccine Initiative at PATH are having interesting discussions about the importance of a vaccine that protects against diarrhoea caused by ETEC.
Ambassador Annika Thunborg, Dr. Alejandro Cravioto, Universidad Nacional Autónoma de México and Member of Scientific Advisory Committee, Professor Ann-Marie Svennerholm and Dr Firdausi Qadri, Director, Center for Vaccine Sciences at icddr,b, Dhaka, discusses the huge global health challenge to reduce child morbidity and mortality related to diarrheal disease caused by ETEC.
Ämnen
Scandinavian Biopharma
Scandinavian Biopharma is a Swedish research-based biotechnology company. The company is together with the American non-profit health organization PATH and researchers at the University of Gothenburg developing a drinkable diarrhea vaccine that protects against ETEC. The company's vision is that the vaccine will save hundreds of thousands of lives in the develoing countries, prevent antibiotic resistance and save the holiday for millions of travelers. Today, there is no ETEC vaccine available to meet these needs. A proof that we are on the right track and that our vaccine project is world-leading is that we are supported by PATH, an important partner of Bill and Melinda Gates Foundation for the development of new vaccines in the field of diarrhea diseases in developing countries. Scandinavian Biopharma also operates as distributor of specialty pharmaceuticals in the Nordic market.
